1
|
El-Khoueiry AB, Trojan J, Meyer T, Yau T, Melero I, Kudo M, Hsu C, Kim TY, Choo SP, Kang YK, Yeo W, Chopra A, Soleymani S, Yao J, Neely J, Tschaika M, Welling TH, Sangro B. Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040. Ann Oncol 2024; 35:381-391. [PMID: 38151184 DOI: 10.1016/j.annonc.2023.12.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2023] [Revised: 12/07/2023] [Accepted: 12/11/2023] [Indexed: 12/29/2023] Open
Abstract
BACKGROUND Patients with advanced hepatocellular carcinoma (aHCC) have a poor prognosis and high mortality. Nivolumab monotherapy demonstrated clinical benefit with an acceptable safety profile in patients with aHCC in the CheckMate 040 study. Five-year follow-up of the sorafenib-naive and sorafenib-experienced groups of CheckMate 040 is presented here. PATIENTS AND METHODS Patients received nivolumab monotherapy at dose levels of 0.1-10.0 mg/kg (dose-escalation phase) or 3 mg/kg (dose-expansion phase) every 2 weeks until disease progression or unacceptable toxicity. Primary endpoints were safety and tolerability (dose escalation), and objective response rate (ORR) by blinded independent central review (BICR) and by investigator as per RECIST version 1.1 (dose expansion). RESULTS Eighty sorafenib-naive and 154 sorafenib-experienced patients were treated. Minimum follow-up in both groups was 60 months. ORR as per BICR was 20% [95% confidence interval (CI) 12% to 30%] and 14% (95% CI 9% to 21%) in the sorafenib-naive and sorafenib-experienced groups, respectively. Responses occurred regardless of HCC etiology or baseline tumor cell programmed death-ligand 1 (PD-L1) expression levels. Median overall survival (OS) was 26.6 months (95% CI 16.6-30.6 months) and 15.1 months (95% CI 13.0-18.2 months) in sorafenib-naive and sorafenib-experienced patients, respectively. The 3-year OS rates were 28% in the sorafenib-naive and 20% in the sorafenib-experienced groups; 5-year OS rates were 14% and 12%, respectively. No new safety signals were identified; grade 3/4 treatment-related adverse events were observed in 33% and 21% of patients in the sorafenib-naive and sorafenib-experienced groups, respectively. Biomarker analyses showed that baseline PD-L1 expression ≥1% was associated with higher ORR and longer OS compared with PD-L1 <1%. In the sorafenib-naive group, patients with OS ≥3 years exhibited higher baseline CD8 T-cell density compared with those with OS <1 year. CONCLUSION With 5 years of follow-up, nivolumab monotherapy continued to provide durable clinical benefit with manageable safety in sorafenib-naive and sorafenib-experienced patients with aHCC.
Collapse
Affiliation(s)
- A B El-Khoueiry
- Division of Medical Oncology, USC Norris Comprehensive Cancer Center, Los Angeles, USA.
| | - J Trojan
- Department of Medicine, Goethe University Hospital and Cancer Center, Frankfurt, Germany
| | - T Meyer
- Department of Oncology, Royal Free Hospital, London, UK
| | - T Yau
- Department of Medicine, University of Hong Kong, Hong Kong, China
| | - I Melero
- Department of Immunology, Clinica Universidad de Navarra and CIBERONC, Pamplona, Spain
| | - M Kudo
- Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan
| | - C Hsu
- Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
| | - T-Y Kim
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
| | - S-P Choo
- Division of Medical Oncology, National Cancer Center and Curie Oncology, Singapore, Republic of Singapore
| | - Y-K Kang
- Department of Oncology, Asan Medical Center, University of Ulsan, Seoul, Korea
| | - W Yeo
- Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, China
| | - A Chopra
- Department of Medical Oncology, Johns Hopkins Singapore International Medical Centre, Singapore, Republic of Singapore
| | - S Soleymani
- Global Biometrics & Data Sciences, Bristol Myers Squibb, Princeton, USA
| | - J Yao
- Informatics and Predictive Sciences, Bristol Myers Squibb, Princeton, USA
| | - J Neely
- Translational Medicine, Bristol Myers Squibb, Princeton, USA
| | - M Tschaika
- Oncology Clinical Development, Bristol Myers Squibb, Princeton, USA
| | - T H Welling
- Perlmutter Cancer Center and Department of Surgery, NYU Langone Health, New York, USA
| | - B Sangro
- Liver Unit and HPB Oncology Area, Clinica Universidad de Navarra and CIBEREHD, Pamplona, Spain
| |
Collapse
|
2
|
Lindner J, Ross U, Meyer T, Boureau V, Seibt M, Jooss C. Reconstruction of Angstrom resolution exit-waves by the application of drift-corrected phase-shifting off-axis electron holography. Ultramicroscopy 2023; 256:113880. [PMID: 37952372 DOI: 10.1016/j.ultramic.2023.113880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2023] [Revised: 10/05/2023] [Accepted: 10/21/2023] [Indexed: 11/14/2023]
Abstract
Phase-shifting electron holography is an excellent method to reveal electron wave phase information with very high phase sensitivity over a large range of spatial frequencies. It circumvents the limiting trade-off between fringe spacing and visibility of standard off-axis holography. Previous implementations have been limited by the independent drift of biprism and sample. We demonstrate here an advanced drift correction scheme for the hologram series that exploits the presence of an interface of the TEM specimen to the vacuum area in the hologram. It allows to obtain reliable phase information up to 2π/452 at the 1 Å information limit of the Titan 80-300 kV environmental transmission electron microscope used, by applying a moderate voltage of 250 V to a single biprism for a fringe spacing of 1 Å. The obtained phase and amplitude information is validated at a thin Pt sample by use of multislice image simulation with the frozen lattice approximation and shows excellent agreement. The presented method is applicable in any TEM equipped with at least one electron biprism and thus enables achieving high resolution off-axis holography in various instruments including those for in-situ applications. A software implementation for the acquisition, calibration and reconstruction is provided.
Collapse
Affiliation(s)
- J Lindner
- Institute of Materials Physics, University of Goettingen, Friedrich-Hund-Platz 1, 37077, Goettingen, Germany
| | - U Ross
- 4th Institute of Physics - Solids and Nanostructures, University of Goettingen, Friedrich-Hund-Platz 1, 37077, Goettingen, Germany
| | - T Meyer
- Institute of Materials Physics, University of Goettingen, Friedrich-Hund-Platz 1, 37077, Goettingen, Germany
| | - V Boureau
- Interdisciplinary Center for Electron Microscopy, École Polytechnique Fédérale de Lausanne, CH-1015, Lausanne, Switzerland
| | - M Seibt
- 4th Institute of Physics - Solids and Nanostructures, University of Goettingen, Friedrich-Hund-Platz 1, 37077, Goettingen, Germany
| | - Ch Jooss
- Institute of Materials Physics, University of Goettingen, Friedrich-Hund-Platz 1, 37077, Goettingen, Germany; International Center for Advanced Studies of Energy Conversion (ICASEC), University of Goettingen, D-37077, Goettingen, Germany.
| |
Collapse
|
3
|
Fullerton RE, Martell K, Khanolkar R, Phan T, Banerjee RN, Meyer T, Traptow L, Köbel M, Ghatage P, Doll CM. Impact of Immune, Inflammatory, and Nutritional Indices on Outcome in Patients with Cervical Cancer Treated with Definitive (Chemo)radiotherapy. Int J Radiat Oncol Biol Phys 2023; 117:e513. [PMID: 37785604 DOI: 10.1016/j.ijrobp.2023.06.1772] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Systemic immune, inflammatory, and nutritional indices have been shown to be prognostic for outcome across a range of tumor sites. However, a comprehensive analysis of these markers in patients with cervical cancer treated with definitive (chemo)radiotherapy [(C)RT] has not been performed. We hypothesized that systemic immune, inflammatory, and nutritional indices may be associated with progression free survival (PFS) and overall survival (OS) in patients undergoing definitive (C)RT for cervical cancer. MATERIALS/METHODS Patients with cervical cancer treated with definitive (C)RT from 1999 - 2015 were identified from a single cancer institution's retrospective clinicopathological database. Pre-treatment immune, inflammatory, and nutritional parameters were collected, and indices derived. Systemic immune-inflammation index (SII) = neutrophil count x platelet count / lymphocyte count(10^9/L); PLR = platelet count / lymphocyte count(10^9/L), NLR = neutrophil count / lymphocyte count (10^9/L); MLR = monocyte count / lymphocyte count (10^9/L); albumin to alkaline phosphatase ratio (AAPR) = serum albumin level (g/L)/alkaline phosphatase level (U/L) and prognostic nutritional index (PNI) = serum albumin (g/L) + 5 x lymphocyte count (10^9/L). Univariate analysis was first performed on each parameter as continuous variables for PFS and OS. For variables with statistically significant associations, ROC curves were analyzed to determine if an optimal cut point could be established for each outcome. Common cut points were then defined for each variable. PFS and OS were analyzed by the Kaplan-Meier method and the Log-Rank test. Multivariate analysis was performed using Cox regression with covariates of tumor stage, histology, and age. P-values of <0.05 were considered statistically significant. RESULTS A total of 196 patients were identified; median follow-up 7 years. 131 (67%) had stage I-II and 65 (33%) stage III-IV disease. 187 (95%) received CRT and 9 (5%) RT alone. Higher SII (≤700 vs >700; p = 0.01), higher PLR (≤ 250 vs >250; p<0.001) and higher NLR (≤ 5 vs >5; p = 0.003) were associated with worse PFS. Higher SII [≤700 vs >700: 5y OS 74.9 vs 55.8; p = 0.02], higher PLR [≤ 250 vs >250: 5y OS 69.9% vs 42.0%; p<0.001] and higher NLR [≤ 5 vs >5: 5y OS 65.3% vs 51.0%; p = 0.01] were associated with worse OS. MLR, AAPR and PNI were not associated with outcome on univariate analysis. On multivariate analysis, SII and PLR were independently associated with both PFS [SII: HR 1.647 (CI 1.029-2.639), p = 0.038; PLR: HR 2.301 (95% CI 1.507 - 3.512), p = <0.001], and OS [SII: HR 1.649 (95% CI 1.009-2.696), p = 0.046; PLR: HR 2.212 (95% CI 1.416-3.455), p<0.001]; NLR did not remain statistically significant. CONCLUSION SII and PLR, but not nutritional indices, were independently associated with PFS and OS in patients with cervical cancer treated with definitive (C)RT. Further evaluation of these systemic immune and inflammatory indices in a validation set will be required to better define their clinical utility.
Collapse
Affiliation(s)
- R E Fullerton
- Department of Oncology, University of Calgary, Calgary, AB, Canada
| | - K Martell
- Department of Oncology, Division of Radiation Oncology, Tom Baker Cancer Center, University of Calgary, Calgary, AB, Canada
| | - R Khanolkar
- Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
| | - T Phan
- Department of Oncology, University of Calgary, Calgary, AB, Canada
| | - R N Banerjee
- Department of Oncology, University of Calgary, Calgary, AB, Canada
| | - T Meyer
- Department of Oncology, University of Calgary, Calgary, AB, Canada; Division of Medical Physics, University of Calgary, Calgary, AB, Canada
| | - L Traptow
- Department of Radiation Therapy, Tom Baker Cancer Centre, Calgary, AB, Canada
| | - M Köbel
- Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada
| | - P Ghatage
- Department of Oncology, University of Calgary, Calgary, AB, Canada; Department of Obstetrics and Gynecology, University of Calgary, Calgary, AB, Canada
| | - C M Doll
- Department of Oncology, University of Calgary, Calgary, AB, Canada
| |
Collapse
|
4
|
Fullerton RE, Martell K, Khanolkar R, Phan T, Banerjee RN, Meyer T, Traptow L, Köbel M, Ghatage P, Doll CM. Hypomagnesemia and Survival in Patients with Cervical Cancer Treated with Definitive Chemoradiotherapy. Int J Radiat Oncol Biol Phys 2023; 117:e513-e514. [PMID: 37785605 DOI: 10.1016/j.ijrobp.2023.06.1773] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Hypomagnesemia is a common side effect of platinum-based chemotherapy regimens. Although there are data reporting that hypomagnesemia is associated with worse survival in patients receiving platinum-based chemotherapy or chemoradiotherapy (CRT), this has not been documented in patients with cervical cancer treated with definitive CRT. We hypothesized that in patients with cervical cancer undergoing definitive CRT, on-treatment hypomagnesemia would be associated with longer treatment duration and worse cancer-specific survival (CSS). MATERIALS/METHODS Patients with cervical cancer treated with definitive CRT from 1999 to 2015 were identified from a single cancer center's clinicopathologic database. Lowest on-treatment magnesium value was recorded and categorized as per Common Terminology Criteria for Adverse Events (CTCAE) v5.0 grading (grade 1: <0.7 - 0.5 mmol/L, grade 2: <0.5 - 0.4 mmol/L, grade 3: <0.4-0.3 mmol/L, and grade 4 <0.3 mmol/L). Grade 0 was defined as ≥ 0.7 mmol/L. Treatment duration was defined as the number of days between the first day of radiotherapy until the last day of pelvic treatment (either brachytherapy or pelvic external beam radiotherapy boost). Prolonged treatment was considered as any treatment duration greater than 63 days. CSS for patients with either grade 0-1 or grade ≥ 2 CTCAE v5.0 magnesium toxicity was estimated using the Kaplan-Meier method, and the Peto & Peto modification to the generalized Gehan-Wilcoxon was used to determine statistical significance between groups. Associations with prolonged treatment duration was explored using logistic regression. P-values of <0.05 were considered statistically significant. RESULTS A total of 186 patients were identified; median follow-up was 7 (IQR 2-11) years. 125 (67%) had stage I-II disease and 61 (33%) stage III-IV. Median treatment duration was 51 (IQR 48-57) days. All patients received concurrent weekly cisplatin-based chemotherapy with RT: the majority (n = 133; 72%) received 5 or 6 cycles. 147 (79%) patients received routine IV magnesium infusion with their chemotherapy and 173 (93%) received routine IV mannitol. During treatment the highest CTCAE v5.0 magnesium toxicity score was grade 0-1 in 158 (85%) and grade ≥ 2 in 28 (15%). Magnesium grade ≥ 2 was associated with worse 5-year CSS [grade 0-1: 5yr CSS 67.2%, (95% CI 60.1-75.1); grade ≥ 2: 5yr CSS 50%, (95% CI 34.5-72.4); p = 0.039]. Magnesium status was not associated with an increase in treatment duration [OR 1.465 (95% CI 0.3177 - 6.753); p = 0.625]. CONCLUSION On-treatment hypomagnesemia ≥ grade 2 (CTCAE v5.0) was associated with worse CSS but did not predict longer treatment duration. This is the first study that shows a detrimental survival impact of on-treatment hypomagnesemia in this patient population. These findings highlight the need to ensure adequate monitoring, support and correction of magnesium during definitive CRT.
Collapse
Affiliation(s)
- R E Fullerton
- Department of Oncology, University of Calgary, Calgary, AB, Canada
| | - K Martell
- Department of Oncology, Division of Radiation Oncology, Tom Baker Cancer Center, University of Calgary, Calgary, AB, Canada
| | - R Khanolkar
- Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
| | - T Phan
- Department of Oncology, University of Calgary, Calgary, AB, Canada
| | - R N Banerjee
- Department of Oncology, University of Calgary, Calgary, AB, Canada
| | - T Meyer
- Department of Oncology, University of Calgary, Calgary, AB, Canada; Division of Medical Physics, University of Calgary, Calgary, AB, Canada
| | - L Traptow
- Department of Radiation Therapy, Tom Baker Cancer Centre, Calgary, AB, Canada
| | - M Köbel
- Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada
| | - P Ghatage
- Department of Oncology, University of Calgary, Calgary, AB, Canada; Department of Obstetrics and Gynecology, University of Calgary, Calgary, AB, Canada
| | - C M Doll
- Department of Oncology, University of Calgary, Calgary, AB, Canada
| |
Collapse
|
5
|
Ghazisaidi H, Wang V, Fatehi P, Tran H, Meyer T, Allen DG. Determining the performance of lignin-based flocculants in improving biosludge dewaterability. J Environ Manage 2023; 325:116509. [PMID: 36308959 DOI: 10.1016/j.jenvman.2022.116509] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/05/2022] [Revised: 10/05/2022] [Accepted: 10/10/2022] [Indexed: 06/16/2023]
Abstract
In the wastewater treatment plant of pulp and paper mills, biosludge dewatering is needed to reduce the sludge handling and disposal costs. It is usually facilitated by means of the addition of synthetic polymers. There is increasing interest in replacing synthetic polymers with biopolymers derived from low value by-products or industrial residuals to improve the environmental footprint of dewatering. In this study, lignin-based flocculants (LBF) were tested for their ability to improve the biosludge dewaterability based on Capillary Suction Time (CST) and dry cake solids achieved with a Crown Press. The results demonstrate that LBFs alone can significantly enhance dewatering with a decrease in CSTs from 72.7 ± 5.1 s (unconditioned biosludge) to 23.3 ± 0.4 s and an increase in dry cake solids after pressing from 7.1 ± 0.5% to 13.9 ± 1.3% with a relatively high dosage of 7.5% w/w. However, with dual conditioning a LBF and 0.1% w/w anionic polyacrylamide (APAM), the required dosage of LBF was reduced to 3% w/w to achieve a dry cake solids content of 13.8 ± 0.4%, the same as that achieved with Zetag8165, a commercial synthetic polymer. LBF addition lowered the particle surface charge, allowing the particles to agglomerate and enhancing for the biosludge dewaterability. The application of LBFs for sludge dewatering offers novel considerable promise for providing more sustainable approaches by optimizing the use of lignin from different extraction processes, applying various types of lignin modifications in combination with anionic polymers, and exploring different methods of disposal or utilization of the dewatered sludge.
Collapse
Affiliation(s)
- Hamed Ghazisaidi
- Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, Ontario, Canada
| | - Vincent Wang
- Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, Ontario, Canada
| | - Pedram Fatehi
- Department of Chemical Engineering, Lakehead University, Thunder Bay, Ontario, Canada
| | - Honghi Tran
- Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, Ontario, Canada
| | - Torsten Meyer
- Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, Ontario, Canada
| | - D Grant Allen
- Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, Ontario, Canada.
| |
Collapse
|
6
|
Ghazisaidi H, Tran H, Meyer T, Allen DG. Enhancement of Biosludge Dewatering using Proteins through Dual Conditioning. CAN J CHEM ENG 2022. [DOI: 10.1002/cjce.24705] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Hamed Ghazisaidi
- Department of Chemical Engineering and Applied Chemistry University of Toronto Toronto Ontario Canada
| | - Honghi Tran
- Department of Chemical Engineering and Applied Chemistry University of Toronto Toronto Ontario Canada
| | - Torsten Meyer
- Department of Chemical Engineering and Applied Chemistry University of Toronto Toronto Ontario Canada
| | - D. Grant Allen
- Department of Chemical Engineering and Applied Chemistry University of Toronto Toronto Ontario Canada
| |
Collapse
|
7
|
Gambichler T, Elfering J, Meyer T, Bruckmüller S, Stockfleth E, Skrygan M, Käfferlein HU, Brüning T, Lang K, Wagener D, Schröder S, Nick M, Susok L. Protein expression of prognostic genes in primary melanoma and benign nevi. J Cancer Res Clin Oncol 2022; 148:2673-2680. [PMID: 34757537 PMCID: PMC9470607 DOI: 10.1007/s00432-021-03779-0] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2021] [Accepted: 08/25/2021] [Indexed: 11/22/2022]
Abstract
PURPOSE To evaluate the protein expression characteristics of genes employed in a recently introduced prognostic gene expression assay for patients with cutaneous melanoma (CM). METHODS We studied 37 patients with CM and 10 with benign (melanocytic) nevi (BN). Immunohistochemistry of primary tumor tissue was performed for eight proteins: COL6A6, DCD, GBP4, KLHL41, KRT9, PIP, SCGB1D2, SCGB2A2. RESULTS The protein expression of most markers investigated was relatively low (e.g., DCD, KRT9, SCGB1D2) and predominantly cytoplasmatic in melanocytes and keratinocytes. COL6A6, GBP4, and KLHL41 expression was significantly enhanced in CM when compared to BN. DCD protein expression was significantly correlated with COL6A6, GBP4, and KLHL41. GBP4 was positively correlated with KLHL41 and inversely correlated with SCGB2B2. The latter was also inversely correlated with serum S100B levels at time of initial diagnosis. The presence of SCGB1D2 expression was significantly associated with ulceration of the primary tumor. KRT9 protein expression was significantly more likely found in acral lentiginous melanoma. The presence of DCD expression was less likely associated with superficial spreading melanoma subtype but significantly associated with non-progressive disease. The absence of SCGB2A2 expression was significantly more often observed in patients who did not progress to stage III or IV. CONCLUSIONS The expression levels observed were relatively low but differed in part with those found in BN. Even though we detected some significant correlations between the protein expression levels and clinical parameters (e.g., CM subtype, course of disease), there was no major concordance with the protective or risk-associated functions of the corresponding genes included in a recently introduced prognostic gene expression assay.
Collapse
Affiliation(s)
- T Gambichler
- Skin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, Germany.
| | - J Elfering
- Skin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, Germany
| | - T Meyer
- Skin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, Germany
| | - S Bruckmüller
- Skin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, Germany
| | - E Stockfleth
- Skin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, Germany
| | - M Skrygan
- Skin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, Germany
| | - H U Käfferlein
- Institute for Prevention and Occupational Medicine of the German Social Accident Insurances, Ruhr-University Bochum (IPA), Bochum, Germany
| | - T Brüning
- Institute for Prevention and Occupational Medicine of the German Social Accident Insurances, Ruhr-University Bochum (IPA), Bochum, Germany
| | - K Lang
- Institute for Prevention and Occupational Medicine of the German Social Accident Insurances, Ruhr-University Bochum (IPA), Bochum, Germany
| | - D Wagener
- Pathology/Labor Lademannbogen MVZ GmbH, Hamburg, Germany
| | - S Schröder
- Pathology/Labor Lademannbogen MVZ GmbH, Hamburg, Germany
| | - M Nick
- Skin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, Germany
| | - L Susok
- Skin Cancer Center, Department of Dermatology, Ruhr-University Bochum, Bochum, Germany
| |
Collapse
|
8
|
Perelroizen R, Philosof B, Budick-Harmelin N, Chernobylsky T, Rotem K, Ron A, Shimon D, Tessler A, Adir O, Gaoni-Yogev A, Meyer T, Madi A, Ruppin E, Mayo L. P12.15.B Astrocyte immunometabolic regulation of the glioblastoma microenvironment drives tumor pathogenicity. Neuro Oncol 2022. [DOI: 10.1093/neuonc/noac174.280] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Malignant brain tumors are the cause of a disproportionate level of morbidity and mortality among cancer patients, an unfortunate statistic that has remained constant for decades. Despite considerable advances in the molecular characterization of these tumors, targeting the cancer cells has yet to produce significant advances in treatment. An alternative strategy is to target cells in the glioblastoma microenvironment, such as tumor associated astrocytes. Astrocytes control multiple processes in health and disease, ranging from maintaining the brain's metabolic homeostasis, to modulating neuroinflammation. However, their role in glioblastoma pathogenicity is not well understood.
Material and Methods
Immunocompetent mice were implanted with murine glioma cell lines and the role of astrocyte in the tumor pathogenicity was analyzed, and further investigated using in-vitro co-cultures.
Results
Here we report that depletion of reactive astrocytes regresses glioblastoma and prolongs mouse survival. Analysis of the tumor-associated astrocyte translatome, revealed that astrocytes initiate transcriptional programs that shape the immune and metabolic compartments in the glioma microenvironment. Specifically, their expression of CCL2 and CSF1 governs the recruitment of tumor-associated macrophages and promotes a pro-tumorigenic macrophage phenotype. Concomitantly, we demonstrate that astrocyte-derived cholesterol is key to glioma cell survival, and that targeting astrocytic cholesterol efflux, via ABCA1, halts tumor progression. In summary, astrocytes control glioblastoma pathogenicity by reprogramming the immunological properties of the tumor microenvironment and supporting the non-oncogenic metabolic dependency of glioblastoma on cholesterol.
Conclusion
These findings suggest that targeting astrocyte immunometabolic signaling may help treat this uniformly lethal brain tumor.
Collapse
Affiliation(s)
| | | | | | | | - K Rotem
- National Cancer Institute , Bethesda, MD , United States
| | - A Ron
- Tel Aviv University , Tel Aviv , Israel
| | - D Shimon
- Tel Aviv University , Tel Aviv , Israel
| | - A Tessler
- Tel Aviv University , Tel Aviv , Israel
| | - O Adir
- Tel Aviv University , Tel Aviv , Israel
| | | | - T Meyer
- Tel Aviv University , Tel Aviv , Israel
| | - A Madi
- Tel Aviv University , Tel Aviv , Israel
| | - E Ruppin
- National Cancer Institute , Bethesda, MD , United States
| | - L Mayo
- Tel Aviv University , Tel Aviv , Israel
| |
Collapse
|
9
|
Ross P, Skabla P, Sutter J, Ibrahim K, Whealon S, Carp N, Walker M, Meyer T. EP02.03-023 Decreasing Time to Definitive Therapy with MIDAS: Minimally Invasive Diagnosis and Surgery. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.379] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
10
|
Finn R, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Cheng AL, Galle P, Kaneko S, Kumada H, Wang A, Mody K, Dubrovsky L, Siegel A, Llovet J. LBA34 Primary results from the phase III LEAP-002 study: Lenvatinib plus pembrolizumab versus lenvatinib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.08.031] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
11
|
Oaknin A, Moore K, Meyer T, González J, Devriese L, Amin A, Lao C, Boni V, Sharfman W, Park J, Tahara M, Topalian S, Magallanes Maciel M, Molina Alavez A, Khan A, Copigneaux C, Lee M, Garnett-Benson C, Wang X, Naumann R. 520MO Safety and efficacy of nivolumab (NIVO) ± ipilimumab (IPI) in patients (pts) with recurrent/metastatic cervical cancer (R/M Cx Ca) in checkmate 358. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.648] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
12
|
Weiß C, Stucke J, Thienel C, Fier M, Ottersbach K, Meyer T. Medizinische Zentren für Erwachsene mit geistiger oder
mehrfacher Behinderung (MZEB) als Orte sozialmedizinischer
Versorgung. Das Gesundheitswesen 2022. [DOI: 10.1055/s-0042-1753612] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
|
13
|
Meyer T, Tappe D, Hasan D, Rust M, Schulz JB, Schiefer J, Tauber SC. „Borna disease virus 1“(BoDV-1)-Enzephalitis eines 18-Jährigen außerhalb des bisher bekannten Endemiegebietes. DGNeurologie 2022. [PMCID: PMC9125534 DOI: 10.1007/s42451-022-00440-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- T. Meyer
- Neurologische Klinik, Universitätsklinikum RWTH Aachen, Pauwelsstr. 30, 52074 Aachen, Deutschland
| | - D. Tappe
- Bernhard-Nocht-Institut für Tropenmedizin, Hamburg, Deutschland
| | - D. Hasan
- Klinik für Diagnostische und Interventionelle Neuroradiologie, Universitätsklinikum RWTH Aachen, Aachen, Deutschland
| | - M. Rust
- Neurologische Klinik, Universitätsklinikum RWTH Aachen, Pauwelsstr. 30, 52074 Aachen, Deutschland
| | - J. B. Schulz
- Neurologische Klinik, Universitätsklinikum RWTH Aachen, Pauwelsstr. 30, 52074 Aachen, Deutschland
| | - J. Schiefer
- Neurologische Klinik, Universitätsklinikum RWTH Aachen, Pauwelsstr. 30, 52074 Aachen, Deutschland
| | - S. C. Tauber
- Neurologische Klinik, Universitätsklinikum RWTH Aachen, Pauwelsstr. 30, 52074 Aachen, Deutschland
| |
Collapse
|
14
|
Herold M, Hecksteden A, Radke D, Goes F, Nopp S, Meyer T, Kempe M. Off-ball behavior in association football: A data-driven model to measure changes in individual defensive pressure. J Sports Sci 2022; 40:1412-1425. [PMID: 35640049 DOI: 10.1080/02640414.2022.2081405] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
This study describes an approach to evaluate the off-ball behaviour of attacking players in association football. The aim was to implement a defensive pressure model to examine an offensive player's ability to create separation from a defender using 1411 high-intensity off-ball actions including 988 Deep Runs (DRs) DRs and 423 Change of Directions (CODs). Twenty-two official matches (14 competitive matches and 8 friendlies) of the German National Team were included in the research. To validate the effectiveness of the pressure model, each pass (n = 25,418) was evaluated for defensive pressure on the receiver at the moment of the pass and for the pass completion rate (R = -.34, p < .001). Next, after assessing the inter-rater reliability (Fleiss Kappa of 80 for DRs and 78 for CODs), three expert raters annotated all DRs and CODs that met the pre-set criteria. A time-series analysis of each DR and COD was calculated to the nearest 0.1 second, finding a slight increase in pressure from the start to the end of the off-ball actions as defenders re-established proximity to the attacker after separation was created. A linear mixed model using run type (DR or COD) as a fixed effect with the local maximum as a fixed effect on a continuous scale resulted in p < 0.001, d = 4.81, CI = 0.63 to 0.67 for the greatest decrease in pressure, p < 0.001, d = 0.143, CI = 9.18 to 10.61 for length of the longest decrease in pressure, and p < 0.001, d = 1.13, CI = 0.90 to 1.11 for the fastest rate of decrease in pressure. As these values pertain to the local maximum, situations with greater starting pressure on the attacker often led to greater subsequent decreases. Furthermore, there was a significant (p < .0001) difference between offensive and defensive positions and the number of off-ball actions. Results suggest the model can be applied to quantify and visualise the pressure exerted on non-ball-possessing players. This approach can be combined with other methods of match analysis, providing practitioners with new opportunities to measure tactical performance in football.
Collapse
Affiliation(s)
- Mat Herold
- Institute of Sports and Preventive Medicine, Saarland University, Saarbrücken, Germany.,Deutscher Fußball-Bund, Frankfurt am Main, Germany
| | - A Hecksteden
- Institute of Sports and Preventive Medicine, Saarland University, Saarbrücken, Germany
| | - D Radke
- Institute of Sports and Preventive Medicine, Saarland University, Saarbrücken, Germany
| | - F Goes
- Center for Human Movement Sciences, University of Groningen, University Medical Center Groningen (UMCG), Groningen, The Netherlands
| | - S Nopp
- Deutscher Fußball-Bund, Frankfurt am Main, Germany
| | - T Meyer
- Institute of Sports and Preventive Medicine, Saarland University, Saarbrücken, Germany
| | - M Kempe
- Center for Human Movement Sciences, University of Groningen, University Medical Center Groningen (UMCG), Groningen, The Netherlands
| |
Collapse
|
15
|
Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, Schirmacher P, Verslype C, Zech CJ, Arnold D, Martinelli E. Corrigendum to "Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up": [Annals of Oncology 29 suppl. 4 (2018) v238-iv255]. Ann Oncol 2022; 33:666. [PMID: 35365377 DOI: 10.1016/j.annonc.2022.03.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Affiliation(s)
- A Vogel
- Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany
| | - A Cervantes
- Department of Medical Oncology, Biomedical Research Institute INCLIVA, University of Valencia, Valencia, Spain
| | - I Chau
- Department of Medicine, Royal Marsden Hospital, Surrey, UK
| | - B Daniele
- Dipartimento di Oncologia, A. O. G. Rummo, Benevento, Italy
| | - J M Llovet
- Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, Mount Sinai Liver Cancer Program, New York, USA; Barcelona-Clínic Liver Cancer Group (BCLC), Unitat d'Hepatologia, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, Universitat de Barcelona, Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain
| | - T Meyer
- Oncology, Royal Free Hospital, London, UK; UCL Cancer Institute, University College London, London, UK
| | - J-C Nault
- Service d'hépatologie, Hôpital Jean Verdier, Bondy, France
| | - U Neumann
- Klinik für Allgemein- und Viszeralchirurgie, Medizinische Fakultät der RWTH Aachen, Germany
| | - J Ricke
- Klinik und Poliklinik für Radiologie, Ludwig-Maximilians-Universität München, Munich, Germany
| | - B Sangro
- Liver Unit, Clinica Universidad de Navarra-IDISNA and CIBEREHD, Pamplona, Spain
| | - P Schirmacher
- Institute of Pathology, University Hospital, Heidelberg, Germany
| | - C Verslype
- Campus Gasthuisberg, UZ Leuven, Leuven, Belgium
| | - C J Zech
- Klinik für Radiologie und Nuklearmedizin Universität Basel, Basel, Switzerland
| | - D Arnold
- Department Oncology, Section Hematology and Palliative Care AK Altona, Asklepios Tumorzentrum Hamburg, Hamburg, Germany
| | - E Martinelli
- Faculty of Medicine, Università della Campania L. Vanvitelli Naples, Caserta, Italy
| | | |
Collapse
|
16
|
Hebestreit H, Zeidler C, Schippers C, de Zwaan M, Deckert J, Heuschmann P, Krauth C, Bullinger M, Berger A, Berneburg M, Brandstetter L, Deibele A, Dieris-Hirche J, Graessner H, Gündel H, Herpertz S, Heuft G, Lapstich AM, Lücke T, Maisch T, Mundlos C, Petermann-Meyer A, Müller S, Ott S, Pfister L, Quitmann J, Romanos M, Rutsch F, Schaubert K, Schubert K, Schulz JB, Schweiger S, Tüscher O, Ungethüm K, Wagner TOF, Haas K, Akkaya F, Babka C, Bârlescu L, Bärsch-Michelmann A, Bergbreiter A, Blömeke J, Böhm L, Böttger B, Braun B, Brinkmann F, Britz V, Cario H, Celiker M, de Greck M, Debatin KM, Dillmann-Jehn K, Ertl M, Ettinger M, Eymann J, Frommer J, Gabrian M, Glode A, Gödecke V, Grasemann C, Grauer E, Greger H, Haas A, Haase M, Haisch L, Heinrich I, Held M, Hennermann J, Herrmann-Werner A, Hett J, Hilbig B, Holthöfer L, Imhof C, Jacob T, Junne F, Karl S, Kassubek J, Kick L, Koschitzki KT, Krassort H, Kratz C, Kristensen K, Kropff B, Kuhn J, Latzko P, Loew T, Lorenz D, Ludolph AC, dos Santos IM, Meyer T, Mohnike K, Monninger M, Musacchio T, Nanciu AN, Nießen M, Nöhre M, Papagianni A, Pfeifer-Duck C, Piduhn LS, Rampp C, Richter A, Rieß O, Schmidt A, Schneider S, Schoels L, Schwalba M, Selig U, Spangenberger A, Sroka A, Steinbüchel T, Stösser S, Suchant S, Vogel M, Volk D, Vollmuth C, Volnov S, Walter S, Warrings B, Weiler C, Witt S, Zajt KK, Zeltner L, Zenker K, Zhang KD, Zipfel S. Dual guidance structure for evaluation of patients with unclear diagnosis in centers for rare diseases (ZSE-DUO): study protocol for a controlled multi-center cohort study. Orphanet J Rare Dis 2022; 17:47. [PMID: 35164804 PMCID: PMC8842899 DOI: 10.1186/s13023-022-02176-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2021] [Accepted: 01/16/2022] [Indexed: 11/12/2022] Open
Abstract
Background In individuals suffering from a rare disease the diagnostic process and the confirmation of a final diagnosis often extends over many years. Factors contributing to delayed diagnosis include health care professionals' limited knowledge of rare diseases and frequent (co-)occurrence of mental disorders that may complicate and delay the diagnostic process. The ZSE-DUO study aims to assess the benefits of a combination of a physician focusing on somatic aspects with a mental health expert working side by side as a tandem in the diagnostic process. Study design This multi-center, prospective controlled study has a two-phase cohort design. Methods Two cohorts of 682 patients each are sequentially recruited from 11 university-based German Centers for Rare Diseases (CRD): the standard care cohort (control, somatic expertise only) and the innovative care cohort (experimental, combined somatic and mental health expertise). Individuals aged 12 years and older presenting with symptoms and signs which are not explained by current diagnoses will be included. Data will be collected prior to the first visit to the CRD’s outpatient clinic (T0), at the first visit (T1) and 12 months thereafter (T2). Outcomes Primary outcome is the percentage of patients with one or more confirmed diagnoses covering the symptomatic spectrum presented. Sample size is calculated to detect a 10 percent increase from 30% in standard care to 40% in the innovative dual expert cohort. Secondary outcomes are (a) time to diagnosis/diagnoses explaining the symptomatology; (b) proportion of patients successfully referred from CRD to standard care; (c) costs of diagnosis including incremental cost effectiveness ratios; (d) predictive value of screening instruments administered at T0 to identify patients with mental disorders; (e) patients’ quality of life and evaluation of care; and f) physicians’ satisfaction with the innovative care approach. Conclusions This is the first multi-center study to investigate the effects of a mental health specialist working in tandem with a somatic expert physician in CRDs. If this innovative approach proves successful, it will be made available on a larger scale nationally and promoted internationally. In the best case, ZSE-DUO can significantly shorten the time to diagnosis for a suspected rare disease. Trial registration ClinicalTrials.gov; Identifier: NCT03563677; First posted: June 20, 2018, https://clinicaltrials.gov/ct2/show/NCT03563677.
Collapse
|
17
|
Chan-Yam K, Meyer T, Scott JA, Basiliko N. Methane production potential of pulp mill sludges: microbial community and substrate constraints. FEMS Microbiol Lett 2022; 368:6498120. [PMID: 34994385 DOI: 10.1093/femsle/fnab161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2021] [Accepted: 01/03/2022] [Indexed: 11/13/2022] Open
Abstract
Sludges from pulp and paper mills represent a major ecological and environmental cost, and anaerobic digestion represents a method of waste reduction and energy recovery for these mills. This study compared methane production potential and microbial communities across 11 primary and biosludges from 5 pulp and paper mills using various mill processes. We measured methane production from sludges in anaerobic batch reactor experiments over 64d. Sludges were incubated with and without added substrate to test for organic substrate limitation versus inhibition of methanogens. Initial microbial communities and changes to community composition were determined using Illumina MiSeq for metabarcoding of bacterial and archaeal 16S rRNA genes. Mean methane production potential varied greatly between sludges (0.002-79 mL CH4 g-1 TS). Among primary sludges, kraft mill sludge produced more methane than other mill types. For these other mills, biosludge produced more methane than primary sludge, which had evidence of methanogen inhibition. Microbial communities and diversity were influenced by the initial community composition, and high methane production was only seen in sludges with high diversity. A number of sludges innately produced substantial methane and may be targets for further modelling and larger-scale testing of anaerobic digestion.
Collapse
Affiliation(s)
- Kelly Chan-Yam
- Laurentian University Department of Biology and the Vale Living with Lakes Centre, Canada
| | - Torsten Meyer
- Laurentian University Department of Biology and the Vale Living with Lakes Centre, Canada
| | - J Ashley Scott
- Laurentian University Department of Biology and the Vale Living with Lakes Centre, Canada.,Laurentian University Bharti School of Engineering, Canada
| | - Nathan Basiliko
- Laurentian University Department of Biology and the Vale Living with Lakes Centre, Canada.,Laurentian University Bharti School of Engineering, Canada
| |
Collapse
|
18
|
Kudo M, Finn R, Ikeda M, Zhu A, Sung M, Baron A, Okusaka T, Kobayashi M, Kumada H, Kaneko S, Pracht M, Meyer T, Nagao S, Saito K, Mody K, Dubrovsky L, Llovet J. 68P A phase Ib study of lenvatinib + pembrolizumab (LEN + PEMBRO) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 116 follow-up analysis. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.10.086] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
19
|
Andersen J, Caccese J, Esopenko C, Fu A, McKay M, Meyer T, Oxenham V, Peek K. The effect of ball characteristics on head impact magnitude during purposeful heading in adolescent male and female football players. J Sci Med Sport 2021. [DOI: 10.1016/j.jsams.2021.09.132] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
20
|
Andersson M, Kluge A, Meyer T, Koumarianou E, Mattsson S. IDAC-ALPHA: AN ALPHA DOSIMETRY SOFTWARE FOR NORMAL ORGANS AND TISSUES. Radiat Prot Dosimetry 2021; 195:327-333. [PMID: 33839784 DOI: 10.1093/rpd/ncab046] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/23/2020] [Revised: 02/20/2021] [Accepted: 03/05/2021] [Indexed: 06/12/2023]
Abstract
Radiopharmaceuticals have been used for the treatment of various forms of cancer since the 1940s. In recent years, the advantages of alpha emitting radionuclides have emerged as a favourable treatment option. However, most alpha emitting radionuclides have long decay chains with long-lived daughter radionuclides. This leads to uncertainties in the dosimetry for normal organs and tissues, when established dosimetry models are employed. The aim of this project is to assign each progeny its own biokinetic behaviour. The novel dosimetry model was applied to 223Ra-dichloride, frequently used for the treatment of patients with metastatic bone disease from castration-resistant prostate cancer. In this dosimetry model, individual biokinetics for each daughter radionuclide was included. This resulted in a decrease in absorbed dose to bone surfaces and red marrow and increased absorbed dose to liver and kidney, when compared with dosimetry models assuming that the daughter nuclides follow the biokinetics of the parent radionuclide.
Collapse
Affiliation(s)
- M Andersson
- Department of Radiation Physics, Institute of Clinical Sciences, Sahlgrenska Cancer Center, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- Medical Radiation Physics, Department of Translational Medicine, Lund University, Skåne University Hospital, SUS Malmö, Sweden
| | - A Kluge
- ABX - CRO advanced pharmaceutical services, Dresden, Germany
| | - T Meyer
- ABX - CRO advanced pharmaceutical services, Dresden, Germany
| | - E Koumarianou
- ABX - CRO advanced pharmaceutical services, Dresden, Germany
| | - S Mattsson
- Medical Radiation Physics, Department of Translational Medicine, Lund University, Skåne University Hospital, SUS Malmö, Sweden
| |
Collapse
|
21
|
Prelog M, Almanzar G, Stern R, Robrade K, Holzer MT, Winzig C, Kleines M, Stiasny K, Meyer T, Speth F, Haas JP. Humoral and cellular immune response to tick-borne-encephalitis (TBE) vaccination depends on booster doses in patients with Juvenile Idiopathic Arthritis (JIA). Vaccine 2021; 39:5918-5927. [PMID: 34462165 DOI: 10.1016/j.vaccine.2021.08.029] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2021] [Revised: 07/29/2021] [Accepted: 08/06/2021] [Indexed: 11/15/2022]
Abstract
Juvenile Idiopathic Arthritis (JIA) patients living in areas with high prevalence of tick-borne-encephalitis-virus-(TBEV)-infection are recommended for administration of inactivated TBE-vaccination. However, there are serious concerns regarding protective vaccine-induced immune responses against TBEV in immunocompromised patients. The present study aimed to analyze the humoral and cellular immune response to TBE-vaccination in previously TBE-vaccinated JIA patients compared to healthy controls (HC) including investigation of IgG-anti-TBEV avidity, neutralization capacity, cellular reactivity by IFNgamma-ELISPOT and cytokine secretion assays. Similar IgG-anti-TBEV antibody concentrations, neutralization titers and cellular reactivity were found between JIA and HC. The number and the early timing of booster vaccinations after primary vaccination had the most prominent effect on neutralizing antibodies in JIA and on IgG-anti-TBEV concentrations in both JIA and HC. Administration of booster vaccinations made it more likely for JIA patients to have IgG-anti-TBEV concentrations ≥165 VIEU/ml and avidities >60%. TNF-alpha inhibitors had a positive and MTX administration a negative effect on humoral immune responses. In conclusion, irrespective of having JIA or not, vaccinated children showed similar humoral and cellular immunity against TBEV several years after primary TBE-vaccination. However, in JIA, booster vaccinations mounted a significantly higher humoral immune response than in JIA without boosters. Our results highlight the need for timely administration of boosters particularly in JIA. Although immunosuppressive treatment at vaccinations in diagnosed JIA had a negative effect mainly on TBEV-specific cellular immunity, most JIA patients mounted a favorable humoral immune response which was maintained over time. Thus, successful TBE-vaccination seems highly feasible in JIA patients with immunosuppressive regimens.
Collapse
Affiliation(s)
- M Prelog
- Department of Pediatrics, University Hospital Wuerzburg, Josef-Schneider-Straße 2, 97080 Wuerzburg, Germany.
| | - G Almanzar
- Department of Pediatrics, University Hospital Wuerzburg, Josef-Schneider-Straße 2, 97080 Wuerzburg, Germany
| | - R Stern
- Department of Pediatrics, University Hospital Wuerzburg, Josef-Schneider-Straße 2, 97080 Wuerzburg, Germany
| | - K Robrade
- Department of Pediatrics, University Hospital Wuerzburg, Josef-Schneider-Straße 2, 97080 Wuerzburg, Germany
| | - M T Holzer
- Department of Pediatrics, University Hospital Wuerzburg, Josef-Schneider-Straße 2, 97080 Wuerzburg, Germany
| | - C Winzig
- Department of Pediatrics, University Hospital Wuerzburg, Josef-Schneider-Straße 2, 97080 Wuerzburg, Germany
| | - M Kleines
- Department of Medical Microbiology, RWTH Aachen, Pauwelsstraße 30, 52074 Aachen, Germany
| | - K Stiasny
- Department of Virology, Medical University Vienna, Kinderspitalgasse 15, 1090 Vienna, Austria
| | - T Meyer
- Pediatric Surgery Unit, Department of Surgery, University Hospital Wuerzburg, Josef-Schneider-Straße 2, 97080 Wuerzburg, Germany
| | - F Speth
- German Center of Pediatric and Adolescent Rheumatology, Gehfeldstraße 24, 82467 Garmisch-Partenkirchen, Germany
| | - J P Haas
- German Center of Pediatric and Adolescent Rheumatology, Gehfeldstraße 24, 82467 Garmisch-Partenkirchen, Germany
| |
Collapse
|
22
|
Stucke J, Thienel C, Weiß C, Fier M, Xyländer M, Meyer T. DIE INANSPRUCHNAHME AMBULANTER VORSORGELEISTUNGEN VON ERWACHSENEN MIT GEISTIGER BEHINDERUNG ODER SCHWEREN MEHRFACHBEHINDERUNGEN. Das Gesundheitswesen 2021. [DOI: 10.1055/s-0041-1732250] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- J Stucke
- Universität Bielefeld, Fakultät für Gesundheitswissenschaften Stiftungsprofessur Rehabilitationswissenschaften
- Rehabilitative Versorgungsforschung
| | - C Thienel
- Universität Bielefeld, Fakultät für Gesundheitswissenschaften Stiftungsprofessur Rehabilitationswissenschaften
- Rehabilitative Versorgungsforschung
| | - C Weiß
- Universität Bielefeld, Fakultät für Gesundheitswissenschaften Stiftungsprofessur Rehabilitationswissenschaften
- Rehabilitative Versorgungsforschung
| | - M Fier
- Universität Bielefeld, Fakultät für Gesundheitswissenschaften Stiftungsprofessur Rehabilitationswissenschaften
- Rehabilitative Versorgungsforschung
| | - M Xyländer
- Universität Bielefeld, Fakultät für Gesundheitswissenschaften Stiftungsprofessur Rehabilitationswissenschaften
- Rehabilitative Versorgungsforschung
- Humboldt-Universität zu Berlin, Kultur-, Sozial- und Bildungswissenschaftliche Fakultät Institut für Rehabilitationswissenschaften, Abteilung Rehabilitationssoziologie
| | - T Meyer
- Universität Bielefeld, Fakultät für Gesundheitswissenschaften Stiftungsprofessur Rehabilitationswissenschaften
- Rehabilitative Versorgungsforschung
| |
Collapse
|
23
|
|
24
|
Meyer T, Brunovsky M, Horacek J, Novak T, Andrashko V, Seifritz E, Olbrich S. Predictive value of heart rate in treatment of major depression with ketamine in two controlled trials. Clin Neurophysiol 2021; 132:1339-1346. [PMID: 33888426 DOI: 10.1016/j.clinph.2021.01.030] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2020] [Revised: 12/30/2020] [Accepted: 01/09/2021] [Indexed: 11/24/2022]
Abstract
OBJECTIVE Ketamine has been shown to be effective in treatment of episodes of major depressive disorder (MDD). This controlled study aimed to analyse the predictive and discriminative power of heart rate (HR) and heart rate variability (HRV) for ketamine treatment in MDD. METHODS In 51 patients, HR and HRV were assessed at baseline before and during ketamine infusion and 24 hours post ketamine infusion. Montgomery-Åsberg Depression Rating Scale (MADRS) was used to assess changes of depressive symptoms. A 30% or 50% reduction of symptoms after 24 hours or within 7 days was defined as response. A linear mixed model was used for analysis. RESULTS Ketamine infusion increased HR and HRV power during and after infusion. Responders to ketamine showed a higher HR during the whole course of investigation, including at baseline with medium effect sizes (Cohen's d = 0.47-0.67). Furthermore, HR and HRV power discriminated between responders and non-responders, while normalized low and high frequencies did not. CONCLUSION The findings show a predictive value of HR and HRV power for ketamine treatment. This further underlines the importance of the autonomous nervous system (ANS) and its possible malfunctions in MDD. SIGNIFICANCE The predictive power of HR and HRV markers should be studied in prospective studies. Neurophysiological markers could improve treatment for MDD via optimizing the choice of treatments.
Collapse
Affiliation(s)
- Torsten Meyer
- Department for Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Psychiatry Zurich, Switzerland
| | - Martin Brunovsky
- National Institute of Mental Health, Klecany, Czech Republic; Charles University, Third Faculty of Medicine, Prague, Czech Republic
| | - Jiri Horacek
- National Institute of Mental Health, Klecany, Czech Republic; Charles University, Third Faculty of Medicine, Prague, Czech Republic
| | - Tomas Novak
- National Institute of Mental Health, Klecany, Czech Republic; Charles University, Third Faculty of Medicine, Prague, Czech Republic
| | - Veronika Andrashko
- National Institute of Mental Health, Klecany, Czech Republic; Charles University, Third Faculty of Medicine, Prague, Czech Republic
| | - Erich Seifritz
- Department for Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Psychiatry Zurich, Switzerland
| | - Sebastian Olbrich
- Department for Psychiatry, Psychotherapy and Psychosomatics, University Hospital of Psychiatry Zurich, Switzerland.
| |
Collapse
|
25
|
Geiselmann D, Meyer T. [Coincidence of hydatid of Morgagni and undescended testis: more common than expected !]. Urologe A 2021; 60:740-745. [PMID: 33575823 DOI: 10.1007/s00120-021-01475-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/18/2021] [Indexed: 10/22/2022]
Abstract
As part of a retrospective data analysis over a period of 6 years, the coincidence of undescended testis and hydatid of Morgagni (appendix testis) was examined on the basis of 814 operated testes. The overall prevalence of hydatids after opening of the testicular envelope of undescended testes was 62.66%. In addition, we were able to establish a correlation between patient age and the hydatid size. According to the results of the study, the size of the hydatid-with growth most likely to be influenced by hormones-can be assumed to be associated with the patient's age.
Collapse
Affiliation(s)
- D Geiselmann
- Abteilung für Kinderchirurgie, Kinderurologie und Kindertraumatologie, Chirurgie I, Zentrum Operative Medizin (ZOM), Universitätsklinikum Würzburg, Oberdürrbacher Straße 6, 97080, Würzburg, Deutschland
| | - T Meyer
- Abteilung für Kinderchirurgie, Kinderurologie und Kindertraumatologie, Chirurgie I, Zentrum Operative Medizin (ZOM), Universitätsklinikum Würzburg, Oberdürrbacher Straße 6, 97080, Würzburg, Deutschland.
| |
Collapse
|
26
|
Banin U, Waiskopf N, Hammarström L, Boschloo G, Freitag M, Johansson EMJ, Sá J, Tian H, Johnston MB, Herz LM, Milot RL, Kanatzidis MG, Ke W, Spanopoulos I, Kohlstedt KL, Schatz GC, Lewis N, Meyer T, Nozik AJ, Beard MC, Armstrong F, Megarity CF, Schmuttenmaer CA, Batista VS, Brudvig GW. Nanotechnology for catalysis and solar energy conversion. Nanotechnology 2021; 32:042003. [PMID: 33155576 DOI: 10.1088/1361-6528/abbce8] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
This roadmap on Nanotechnology for Catalysis and Solar Energy Conversion focuses on the application of nanotechnology in addressing the current challenges of energy conversion: 'high efficiency, stability, safety, and the potential for low-cost/scalable manufacturing' to quote from the contributed article by Nathan Lewis. This roadmap focuses on solar-to-fuel conversion, solar water splitting, solar photovoltaics and bio-catalysis. It includes dye-sensitized solar cells (DSSCs), perovskite solar cells, and organic photovoltaics. Smart engineering of colloidal quantum materials and nanostructured electrodes will improve solar-to-fuel conversion efficiency, as described in the articles by Waiskopf and Banin and Meyer. Semiconductor nanoparticles will also improve solar energy conversion efficiency, as discussed by Boschloo et al in their article on DSSCs. Perovskite solar cells have advanced rapidly in recent years, including new ideas on 2D and 3D hybrid halide perovskites, as described by Spanopoulos et al 'Next generation' solar cells using multiple exciton generation (MEG) from hot carriers, described in the article by Nozik and Beard, could lead to remarkable improvement in photovoltaic efficiency by using quantization effects in semiconductor nanostructures (quantum dots, wires or wells). These challenges will not be met without simultaneous improvement in nanoscale characterization methods. Terahertz spectroscopy, discussed in the article by Milot et al is one example of a method that is overcoming the difficulties associated with nanoscale materials characterization by avoiding electrical contacts to nanoparticles, allowing characterization during device operation, and enabling characterization of a single nanoparticle. Besides experimental advances, computational science is also meeting the challenges of nanomaterials synthesis. The article by Kohlstedt and Schatz discusses the computational frameworks being used to predict structure-property relationships in materials and devices, including machine learning methods, with an emphasis on organic photovoltaics. The contribution by Megarity and Armstrong presents the 'electrochemical leaf' for improvements in electrochemistry and beyond. In addition, biohybrid approaches can take advantage of efficient and specific enzyme catalysts. These articles present the nanoscience and technology at the forefront of renewable energy development that will have significant benefits to society.
Collapse
Affiliation(s)
- U Banin
- The Institute of Chemistry and the Center for Nanoscience and Nanotechnology, The Hebrew University of Jerusalem, Jerusalem 91904, Israel
| | - N Waiskopf
- The Institute of Chemistry and the Center for Nanoscience and Nanotechnology, The Hebrew University of Jerusalem, Jerusalem 91904, Israel
| | - L Hammarström
- Department of Chemistry-Ångström Laboratory, Uppsala University, Box 523, SE-75120 Uppsala, Sweden
| | - G Boschloo
- Department of Chemistry-Ångström Laboratory, Uppsala University, Box 523, SE-75120 Uppsala, Sweden
| | - M Freitag
- Department of Chemistry-Ångström Laboratory, Uppsala University, Box 523, SE-75120 Uppsala, Sweden
| | - E M J Johansson
- Department of Chemistry-Ångström Laboratory, Uppsala University, Box 523, SE-75120 Uppsala, Sweden
| | - J Sá
- Department of Chemistry-Ångström Laboratory, Uppsala University, Box 523, SE-75120 Uppsala, Sweden
| | - H Tian
- Department of Chemistry-Ångström Laboratory, Uppsala University, Box 523, SE-75120 Uppsala, Sweden
| | - M B Johnston
- Department of Physics, University of Oxford, Clarendon Laboratory, Parks Road, Oxford OX1 3PU, United Kingdom
| | - L M Herz
- Department of Physics, University of Oxford, Clarendon Laboratory, Parks Road, Oxford OX1 3PU, United Kingdom
| | - R L Milot
- Department of Physics, University of Warwick, Gibbet Hill Road, Coventry CV4 7AL, United Kingdom
| | - M G Kanatzidis
- Department of Chemistry, Northwestern University, Evanston, IL 60208, United States of America
| | - W Ke
- Department of Chemistry, Northwestern University, Evanston, IL 60208, United States of America
| | - I Spanopoulos
- Department of Chemistry, Northwestern University, Evanston, IL 60208, United States of America
| | - K L Kohlstedt
- Department of Chemistry, Northwestern University, Evanston, IL 60208, United States of America
| | - G C Schatz
- Department of Chemistry, Northwestern University, Evanston, IL 60208, United States of America
| | - N Lewis
- Division of Chemistry and Chemical Engineering, and Beckman Institute, 210 Noyes Laboratory, 127-72 California Institute of Technology, Pasadena, CA 91125, United States of America
| | - T Meyer
- University of North Carolina at Chapel Hill, Department of Chemistry, United States of America
| | - A J Nozik
- National Renewable Energy Laboratory, United States of America
- University of Colorado, Boulder, CO, Department of Chemistry, 80309, United States of America
| | - M C Beard
- National Renewable Energy Laboratory, United States of America
| | - F Armstrong
- Department of Chemistry, University of Oxford, Oxford, United Kingdom
| | - C F Megarity
- Department of Chemistry, University of Oxford, Oxford, United Kingdom
| | - C A Schmuttenmaer
- Department of Chemistry, Yale University, 225 Prospect St, New Haven, CT, 06520-8107, United States of America
| | - V S Batista
- Department of Chemistry, Yale University, 225 Prospect St, New Haven, CT, 06520-8107, United States of America
| | - G W Brudvig
- Department of Chemistry, Yale University, 225 Prospect St, New Haven, CT, 06520-8107, United States of America
| |
Collapse
|
27
|
Fields T, Patterson M, Bremova-Ertl T, Belcher G, Billington I, Churchill GC, Davis W, Evans W, Flint S, Galione A, Granzer U, Greenfield J, Karl R, Kay R, Lewi D, Mathieson T, Meyer T, Pangonis D, Platt FM, Tsang L, Verburg C, Factor M, Strupp M. A master protocol to investigate a novel therapy acetyl-L-leucine for three ultra-rare neurodegenerative diseases: Niemann-Pick type C, the GM2 gangliosidoses, and ataxia telangiectasia. Trials 2021; 22:84. [PMID: 33482890 PMCID: PMC7821839 DOI: 10.1186/s13063-020-05009-3] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2020] [Accepted: 12/28/2020] [Indexed: 12/21/2022] Open
Abstract
BACKGROUND The lack of approved treatments for the majority of rare diseases is reflective of the unique challenges of orphan drug development. Novel methodologies, including new functionally relevant endpoints, are needed to render the development process more feasible and appropriate for these rare populations and thereby expedite the approval of promising treatments to address patients' high unmet medical need. Here, we describe the development of an innovative master protocol and primary outcome assessment to investigate the modified amino acid N-acetyl-L-leucine (Sponsor Code: IB1001) in three separate, multinational, phase II trials for three ultra-rare, autosomal-recessive, neurodegenerative disorders: Niemann-Pick disease type C (NPC), GM2 gangliosidoses (Tay-Sachs and Sandhoff disease; "GM2"), and ataxia telangiectasia (A-T). METHODS/DESIGN The innovative IB1001 master protocol and novel CI-CS primary endpoints were developed through a close collaboration between the Industry Sponsor, Key Opinion Leaders, representatives of the Patient Communities, and National Regulatory Authorities. As a result, the open-label, rater-blinded study design is considerate of the practical limitations of recruitment and retention of subjects in these ultra-orphan populations. The novel primary endpoint, the Clinical Impression of Change in Severity© (CI-CS), accommodates the heterogenous clinical presentation of NPC, GM2, and A-T: at screening, the principal investigator appoints for each patient a primary anchor test (either the 8-m walk test (8MWT) or 9-hole peg test of the dominant hand (9HPT-D)) based on his/her unique clinical symptoms. The anchor tests are videoed in a standardized manner at each visit to capture all aspects related to the patient's functional performance. The CI-CS assessment is ultimately performed by independent, blinded raters who compare videos of the primary anchor test from three periods: baseline, the end of treatment, and the end of a post-treatment washout. Blinded to the time point of each video, the raters make an objective comparison scored on a 7-point Likert scale of the change in the severity of the patient's neurological signs and symptoms from video A to video B. To investigate both the symptomatic and disease-modifying effects of treatment, N-acetyl-L-leucine is assessed during two treatment sequences: a 6-week parent study and 1-year extension phase. DISCUSSION The novel CI-CS assessment, developed through a collaboration of all stakeholders, is advantageous in that it better ensures the primary endpoint is functionally relevant for each patient, is able to capture small but meaningful clinical changes critical to the patients' quality of life (fine-motor skills; gait), and blinds the primary outcome assessment. The results of these three trials will inform whether N-acetyl-L-leucine is an effective treatment for NPC, GM2, and A-T and can also serve as a new therapeutic paradigm for the development of future treatments for other orphan diseases. TRIAL REGISTRATION The three trials (IB1001-201 for Niemann-Pick disease type C (NPC), IB1001-202 for GM2 gangliosidoses (Tay-Sachs and Sandhoff), IB1001-203 for ataxia telangiectasia (A-T)) have been registered at www.clinicaltrials.gov (NCT03759639; NCT03759665; NCT03759678), www.clinicaltrialsregister.eu (EudraCT: 2018-004331-71; 2018-004406-25; 2018-004407-39), and https://www.germanctr.de (DR KS-ID: DRKS00016567; DRKS00017539; DRKS00020511).
Collapse
Affiliation(s)
- T. Fields
- IntraBio Ltd, Begbroke Science Park, Begbroke Hill, Woodstock Road, Oxford, OX5 1PF UK
| | - M. Patterson
- Mayo Clinic, 200 First Street SW, Rochester, MN 55905 USA
| | - T. Bremova-Ertl
- Department of Neurology, Inselspital, University Hospital Bern and University of Bern, Bern, Switzerland
| | - G. Belcher
- PV Consultancy, 113 St Georges Square Mews, London, SW1V 3RZ UK
| | - I. Billington
- IntraBio Ltd, Begbroke Science Park, Begbroke Hill, Woodstock Road, Oxford, OX5 1PF UK
| | - G. C. Churchill
- Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, OX1 3QT UK
| | - W. Davis
- Ataxia-Telangiectasia Society, Rothamsted Experimental Station West Common, Harpenden, AL5 2JQ UK
| | - W. Evans
- Niemann-Pick UK, Vermont House, Concord, Washington, Tyne and Wear NE37 2SQ UK
- Primary Care Stratified Medicine (PRISM) Division of Primary Care, University of Nottingham, Nottingham, UK
| | - S. Flint
- IntraBio Ltd, Begbroke Science Park, Begbroke Hill, Woodstock Road, Oxford, OX5 1PF UK
| | - A. Galione
- Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, OX1 3QT UK
| | - U. Granzer
- Granzer Regulatory Consulting & Services, Kistlerhofstr. 172C, D-81379 Munich, Germany
| | | | - R. Karl
- Cure Tay-Sachs Foundation, 2409 E. Luke Avenue, Phoenix, AZ 85016 USA
| | - R. Kay
- RK Statistics, Brook House, Mesne Lane, Bakewell, DE45 1AL UK
| | - D. Lewi
- The Cure & Action for Tay-Sachs Foundation, 94 Milborough Crescent, Lee, London, SE12 0RW UK
| | - T. Mathieson
- International Niemann-Pick Disease Alliance, Vermont House, Concord, Washington, Tyne and Wear NE37 2SQ UK
| | - T. Meyer
- Granzer Regulatory Consulting & Services, Kistlerhofstr. 172C, D-81379 Munich, Germany
| | - D. Pangonis
- National Tay-Sachs and Allied Disease Foundation, 2001 Beacon Street, Suite 204, Boston, MA 02135 USA
| | - F. M. Platt
- Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, OX1 3QT UK
| | - L. Tsang
- Arnold & Porter Kaye Scholer LLP, 25 Old Broad Street, London, EC2N 1HQ UK
| | - C. Verburg
- IntraBio Ltd, Begbroke Science Park, Begbroke Hill, Woodstock Road, Oxford, OX5 1PF UK
| | - M. Factor
- IntraBio Ltd, Begbroke Science Park, Begbroke Hill, Woodstock Road, Oxford, OX5 1PF UK
| | - M. Strupp
- Department of Neurology and German Center for Vertigo and Balance Disorders, University Hospital, Ludwig Maximilians University, Munich, Germany
| |
Collapse
|
28
|
Gallieni M, Hollenbeck M, Inston N, Kumwenda M, Powell S, Tordoir J, Al Shakarchi J, Berger P, Bolignano D, Cassidy D, Chan TY, Dhondt A, Drechsler C, Ecder T, Finocchiaro P, Haller M, Hanko J, Heye S, Ibeas J, Jemcov T, Kershaw S, Khawaja A, Labriola L, Lomonte C, Malovrh M, Marti I Monros A, Matthew S, McGrogan D, Meyer T, Mikros S, Nistor I, Planken N, Roca-Tey R, Ross R, Troxler M, van der Veer S, Vanholder R, Vermassen F, Welander G, Wilmink T, Koobasi M, Fox J, Van Biesen W, Nagler E. Clinical practice guideline on peri- and postoperative care of arteriovenous fistulas and grafts for haemodialysis in adults. Nephrol Dial Transplant 2020; 35:2203. [PMID: 32365363 DOI: 10.1093/ndt/gfaa106] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
29
|
Overton E, Lawrence S, Stapleton J, Weidenthaler H, Schmidt D, Nopora K, Meyer T, Maclennan J, Koenen B, Silbernagl G, Volkmann A, Chaplin P. MVA-BN as monkeypox vaccine for healthy and immunocompromised. Int J Infect Dis 2020. [DOI: 10.1016/j.ijid.2020.09.1217] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
30
|
Hessam S, Gambichler T, Skrygan M, Scholl L, Sand M, Meyer T, Stockfleth E, Bechara F. Increased expression profile of NCSTN, Notch and PI3K/AKT3 in hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2020; 35:203-210. [DOI: 10.1111/jdv.16962] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2020] [Accepted: 09/14/2020] [Indexed: 12/27/2022]
Affiliation(s)
- S. Hessam
- Department of Dermatology, Venereology and Allergology Ruhr‐University Bochum Bochum Germany
- Department of Dermatology and Phlebology Katharinen‐Hospital Unna Unna Germany
| | - T. Gambichler
- Department of Dermatology, Venereology and Allergology Ruhr‐University Bochum Bochum Germany
| | - M. Skrygan
- Department of Dermatology, Venereology and Allergology Ruhr‐University Bochum Bochum Germany
| | - L. Scholl
- Department of Dermatology, Venereology and Allergology Ruhr‐University Bochum Bochum Germany
| | - M. Sand
- Department of Dermatology, Venereology and Allergology Ruhr‐University Bochum Bochum Germany
- Department of Plastic and Reconstructive Surgery St. Josef‐Hospital Essen‐Kupferdreh Germany
| | - T. Meyer
- Department of Dermatology, Venereology and Allergology Ruhr‐University Bochum Bochum Germany
| | - E. Stockfleth
- Department of Dermatology, Venereology and Allergology Ruhr‐University Bochum Bochum Germany
| | - F.G. Bechara
- Department of Dermatology, Venereology and Allergology Ruhr‐University Bochum Bochum Germany
| |
Collapse
|
31
|
Serfling S, Zhi Y, Schirbel A, Lindner T, Meyer T, Gerhard-Hartmann E, Lapa C, Hagen R, Hackenberg S, Buck AK, Scherzad A. Improved cancer detection in Waldeyer's tonsillar ring by 68Ga-FAPI PET/CT imaging. Eur J Nucl Med Mol Imaging 2020; 48:1178-1187. [PMID: 33057927 PMCID: PMC8041699 DOI: 10.1007/s00259-020-05055-8] [Citation(s) in RCA: 44] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2020] [Accepted: 09/24/2020] [Indexed: 12/24/2022]
Abstract
Purpose In cancer of unknown primary (CUP), positron emission tomography/computed tomography (PET/CT) with the glucose analog [18F]FDG represents the standard imaging approach for localization of the malignant primary. Frequently, however, [18F]FDG PET/CT cannot precisely distinguish between small occult tumors and chronic inflammation, especially in Waldeyer’s tonsillar ring. To improve the accuracy for detecting primary tumors in the Waldeyer’s tonsillar ring, the novel PET tracer [68Ga]Ga-FAPI-4 for specific imaging of fibroblast activation protein (FAP) expression was used as a more specific target for cancer imaging. Methods Eight patients with suspicion of a malignant tumor in Waldeyer’s tonsillar ring or a CUP syndrome were examined. PET/CT scans with [18F]-FDG and [68Ga]Ga-FAPI-4 were performed for pre-operative tumor localization. After surgical resection, histopathological and immunohistochemical results were compared to PET/CT findings. Results Histopathology revealed a palatine or lingual tonsil carcinoma in all patients. In case of lymph node metastases smaller than 7 mm in size, the [18F]FDG PET/CT detection rate of cervical lymph node metastases was higher than that of [68Ga]FAPI PET/CT, while both tracers identified the primary tumors in all eight cases. The size of the primary and the lymph node metastases was directly correlated to the respective FAP expression, as detected by immunohistochemistry. The mean SUVmax for the primary tumors was 21.29 ± 7.97 for 18F-FDG and 16.06 ± 6.29 for 68Ga-FAPI, respectively (p = 0.2). The mean SUVmax for the healthy contralateral tonsils was 8.38 ± 2.45 for [18F]FDG and 3.55 ± 0.47 for [68Ga]FAPI (p < 0.001). The SUVmax ratio of [68Ga]FAPI was significantly different from [18F] FDG (p = 0.03). Mean TBRmax for the [68Ga]Ga-FAPI-4 tracer was markedly higher in comparison to [18F]FDG (10.90 vs. 4.11). Conclusion Non-invasive imaging of FAP expression by [68Ga]FAPI PET/CT resulted in a better visual detection of the malignant primary in CUP, as compared to [18F]FDG imaging. However, the detection rate of lymph node metastases was inferior, presumably due to low FAP expression in small metastases. Nevertheless, by offering a detection method for primary tumors with the potential of lower false positive rates and thus avoiding biopsies, patients with CUP syndrome may benefit from [68Ga]FAPI PET/CT imaging.
Collapse
Affiliation(s)
- S Serfling
- Department of Nuclear Medicine, University Hospital Wuerzburg, Oberduerrbacher Str. 6, 97080, Wuerzburg, Germany.
| | - Y Zhi
- Department of Otorhinolaryngology, Plastic, Aesthetic and Reconstructive Head and Neck Surgery, Julius Maximilian University of Wuerzburg, 97080, Wuerzburg, Germany
| | - A Schirbel
- Department of Nuclear Medicine, University Hospital Wuerzburg, Oberduerrbacher Str. 6, 97080, Wuerzburg, Germany
| | - T Lindner
- Department of Nuclear Medicine, University Hospital Heidelberg, 69120, Heidelberg, Germany
| | - T Meyer
- Department of Otorhinolaryngology, Plastic, Aesthetic and Reconstructive Head and Neck Surgery, Julius Maximilian University of Wuerzburg, 97080, Wuerzburg, Germany
| | - E Gerhard-Hartmann
- Department of Pathology and Comprehensive Cancer Center Mainfranken, Julius Maximilian University of Wuerzburg, 97080, Wuerzburg, Germany
| | - C Lapa
- Department of Nuclear Medicine, University Hospital Augsburg, 86156, Augsburg, Germany
| | - R Hagen
- Department of Otorhinolaryngology, Plastic, Aesthetic and Reconstructive Head and Neck Surgery, Julius Maximilian University of Wuerzburg, 97080, Wuerzburg, Germany
| | - S Hackenberg
- Department of Otorhinolaryngology, Plastic, Aesthetic and Reconstructive Head and Neck Surgery, Julius Maximilian University of Wuerzburg, 97080, Wuerzburg, Germany
| | - A K Buck
- Department of Nuclear Medicine, University Hospital Wuerzburg, Oberduerrbacher Str. 6, 97080, Wuerzburg, Germany
| | - A Scherzad
- Department of Otorhinolaryngology, Plastic, Aesthetic and Reconstructive Head and Neck Surgery, Julius Maximilian University of Wuerzburg, 97080, Wuerzburg, Germany
| |
Collapse
|
32
|
Wong B, Webb C, Fahey M, Meyer T, Laraja K, Kashtan C, Salerno A, Shellenbarger K, Gupta N. DMD & BMD – CLINICAL. Neuromuscul Disord 2020. [DOI: 10.1016/j.nmd.2020.08.052] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
33
|
Swindell W, Meyer T, Premi S, Bojanowski K, Chaudhuri R. 851 Acetyl zingerone opposes deleterious effects of skin aging by bolstering matrisome synthesis, neutralizing oxidative stress and inhibiting DNA damage. J Invest Dermatol 2020. [DOI: 10.1016/j.jid.2020.03.867] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
34
|
Dejonckheere G, Suppa M, Del Marmol V, Meyer T, Stockfleth E. The actinic dysplasia syndrome - diagnostic approaches defining a new concept in field carcinogenesis with multiple cSCC. J Eur Acad Dermatol Venereol 2020; 33 Suppl 8:16-20. [PMID: 31833608 DOI: 10.1111/jdv.15949] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2019] [Accepted: 08/23/2019] [Indexed: 12/19/2022]
Abstract
Usually, SCC lesions are surrounded by a number of clinically visible and non-visible (subclinical) areas of actinically damaged skin containing cells with dysplasia, and thus may be designated actinic dysplasia syndrome. The epithelial damage is caused mainly by UV radiation, inducing mutations in keratinocytes that may confer growth advantages resulting in preneoplastic fields. The development of visible dysplastic lesions (actinic keratosis - AK) and subsequent progression to invasive SCC requires further mutations in cancer-associated genes, like tumour suppressor genes and cell cycle regulators. Reflectance confocal microscopy (RCM) and optical coherence tomography (OCT) represent a considerable advantage for the investigation of field cancerization. In addition, imaging allows the non-invasive monitoring of topical treatments for AKs. RCM provides in vivo horizontal skin sections with a high, 1-μm lateral resolution (similar to histopathology) but with a limited penetration (about 200 μm), which can hamper the visualization of important areas such as the dermal-epidermal junction. Conventional OCT has better penetration (1-2 mm) at the expense of a more limited resolution (much lower than histopathology). Line-field confocal OCT (LC-OCT) combines the high precision of RCM and the good penetration of OCT in a single device and therefore appears to be very useful in diagnosing/managing AKs.
Collapse
Affiliation(s)
- G Dejonckheere
- Department of Dermatology and Venerology, Erasme Hospital, Free University of Brussels, Brussels, Belgium
| | - M Suppa
- Department of Dermatology and Venerology, Erasme Hospital, Free University of Brussels, Brussels, Belgium
| | - V Del Marmol
- Department of Dermatology and Venerology, Erasme Hospital, Free University of Brussels, Brussels, Belgium
| | - T Meyer
- Department of Dermatology, Venerology and Allergology, St. Josef Hospital, Ruhr-University, Bochum, Germany
| | - E Stockfleth
- Department of Dermatology, Venerology and Allergology, St. Josef Hospital, Ruhr-University, Bochum, Germany
| |
Collapse
|
35
|
Nieß AM, Bloch W, Friedmann-Bette B, Grim C, Halle M, Hirschmüller A, Kopp C, Meyer T, Niebauer J, Reinsberger C, Röcker K, Scharhag J, Scherr J, Schneider C, Steinacker JM, Urhausen A, Wolfarth B, Mayer F. Position stand: return to sport in the current Coronavirus pandemic (SARS-CoV-2 / COVID-19). Dtsch Z Sportmed 2020. [DOI: 10.5960/dzsm.2020.437] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
36
|
Nieß AM, Bloch W, Friedmann-Bette B, Grim C, Gärtner B, Halle M, Hirschmüller A, Kopp C, Meyer T, Niebauer J, Predel G, Reinsberger C, Röcker K, Scharhag J, Schneider C, Scherr J, Steinacker JM, Mayer F, Wolfarth B. Recommendations for exercise testing in sports medicine during the current pandemic situation (SARS-CoV-2 / COVID-19). Dtsch Z Sportmed 2020. [DOI: 10.5960/dzsm.2020.438] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
37
|
Hessam S, Gambichler T, Höxtermann S, Skrygan M, Sand M, Garcovich S, Meyer T, Stockfleth E, Bechara F. Frequency of circulating subpopulations of T‐regulatory cells in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2020; 34:834-838. [DOI: 10.1111/jdv.16071] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2019] [Accepted: 10/24/2019] [Indexed: 12/14/2022]
Affiliation(s)
- S. Hessam
- Department of Dermatology, Venereology and Allergology Ruhr‐University Bochum Bochum Germany
| | - T. Gambichler
- Department of Dermatology, Venereology and Allergology Ruhr‐University Bochum Bochum Germany
| | - S. Höxtermann
- Department of Dermatology, Venereology and Allergology Ruhr‐University Bochum Bochum Germany
| | - M. Skrygan
- Department of Dermatology, Venereology and Allergology Ruhr‐University Bochum Bochum Germany
| | - M. Sand
- Department of Dermatology, Venereology and Allergology Ruhr‐University Bochum Bochum Germany
- Department of Plastic and Reconstructive Surgery St. Josef‐Hospital Essen‐Kupferdreh Germany
| | - S. Garcovich
- Institute of Dermatology F. Policlinico Gemelli IRCCS Università Cattolica del Sacro Cuore Rome Italy
| | - T. Meyer
- Department of Dermatology, Venereology and Allergology Ruhr‐University Bochum Bochum Germany
| | - E. Stockfleth
- Department of Dermatology, Venereology and Allergology Ruhr‐University Bochum Bochum Germany
| | - F.G. Bechara
- Department of Dermatology, Venereology and Allergology Ruhr‐University Bochum Bochum Germany
| |
Collapse
|
38
|
Mariani S, Napp C, Meyer T, Brandes K, Baum C, Göttel P, Hanke J, Merzah A, Al Masarani M, Tong L, Haverich A, Dogan G, Müller J, Schmitto J. Animal Model of Cardiac Reperfusion Injury to Evaluate the Effects of Electrical Microcurrent Application: Preliminary Results. J Heart Lung Transplant 2020. [DOI: 10.1016/j.healun.2020.01.436] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
39
|
Steinacker JM, Bloch W, Halle H, Mayer F, Meyer T, Hirschmüller A, Röcker K, Nieß A, Scharhag J, Reinsberger C, Scherr J, Niebauer J, Wolfarth B, Hannafin J, Hiura M, Wilkinson M, Koubaa D, Poli P, Smoljanovic T, Nielsen HB, Ackerman K, Wilson F. Fact Sheet: Health Situation for Athletes in the Current Coronavirus Pandemic (SARS-CoV-2 / COVID-19). Dtsch Z Sportmed 2020. [DOI: 10.5960/dzsm.2020.431] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
40
|
Duttge G, Meyer T. [Physician's obligations to inform about complications based on a recent warning from drug authorities]. Med Klin Intensivmed Notfmed 2020; 116:332-338. [PMID: 32034432 PMCID: PMC8102277 DOI: 10.1007/s00063-020-00656-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2019] [Revised: 11/15/2019] [Accepted: 12/22/2019] [Indexed: 11/01/2022]
Abstract
BACKGROUND Based on a recent warning from the drug authorities about increased suicidality among users of hormonal contraceptives, this article discusses the legal consequences of translating novel findings from clinical trials into altered contents of gaining informed consent during the medical consultation. METHODS AND RESULTS Comprehensive information in accordance with § 630e German Civil Code (BGB) requires that rare drug reactions be mentioned by the prescribing physician, when they are associated with serious sequelae. This act regulates the treating physician's obligations to inform about complications for both preventive and curative treatment options. In this paper, we refer to the scientific evidence level of data from clinical trials as the key feature for implementing altered medical information in the proper conduct of acquiring the consent of the patient in line with § 630e BGB. The article discusses how additions and amendments to the package leaflet and the expert information will impact on the obligations for the treating party to provide information for the patient in order to obtain informed consent. In particular, we focus on the relationship between the obligations for the physician prescribing oral contraceptives on an individual case and the generalized information conditions according to § 11 and § 11a German Medicinal Products Act. DISCUSSION Current warnings of the drug authorities in the form of red-hand letters do not necessarily have legal consequences for gaining informed consent during the medical consultation.
Collapse
Affiliation(s)
- G Duttge
- Zentrum für Medizinrecht, Georg-August-Universität Göttingen, Göttingen, Deutschland
| | - T Meyer
- Klinik für Psychosomatische Medizin und Psychotherapie, Georg-August-Universität Göttingen, Waldweg 33, 37073, Göttingen, Deutschland.
| |
Collapse
|
41
|
Gutenbrunner C, Nugraha B, Gimigliano F, Meyer T, Kiekens C. International Classification of Service Organization in Rehabilitation: An updated set of categories (ICSO-R 2.0). J Rehabil Med 2020; 52:jrm00004. [DOI: 10.2340/16501977-2627] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
42
|
Chaudhuri RK, Meyer T, Premi S, Brash D. Acetyl zingerone: An efficacious multifunctional ingredient for continued protection against ongoing DNA damage in melanocytes after sun exposure ends. Int J Cosmet Sci 2019; 42:36-45. [PMID: 31538664 PMCID: PMC7004018 DOI: 10.1111/ics.12582] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2019] [Revised: 09/06/2019] [Accepted: 09/16/2019] [Indexed: 11/26/2022]
Abstract
Objective Recent research has shown that significant levels of cyclobutane pyrimidine dimers (CPDs) in DNA continue to form in melanocytes for several hours in the dark after exposure to ultraviolet radiation (UVR) ends. We document the utility of a new multifunctional ingredient, 3‐(4‐hydroxy, 3‐methoxybenzyl)‐pentane‐2,4‐dione (INCI acetyl zingerone (AZ)), to protect melanocytes against CPD formation after UVR exposure ends. Methods The use of AZ as an intervention to reduce CPD formation after irradiation was assessed in vitro by comparing kinetic profiles of CPD formation for several hours after irradiation in cells that were untreated or treated with AZ immediately after irradiation. Multifunctional performance of AZ as an antioxidant, quencher and scavenger was established using industry‐standard in vitro chemical assays, and then, its efficacy in a more biological assay was confirmed by its in vitro ability to reduce intracellular levels of reactive oxygen species (ROS) in keratinocytes exposed to UVA radiation. Molecular photostability was assessed in solution during exposure to solar‐simulated UVR and compared with the conventional antioxidant α‐tocopherol. Results Even when added immediately after irradiation, AZ significantly inhibited ongoing formation of CPDs in melanocytes after exposure to UVA. Incubation with AZ before irradiation decreased intracellular levels of UVA‐induced ROS formation in keratinocytes. Compared with α‐tocopherol, the molecular structure of AZ endows it with significantly better photostability and efficacy to neutralize free radicals (∙OH, ∙OOH), physically quench singlet oxygen (1O2) and scavenge peroxynitrite (ONOO−). Conclusion These results designate AZ as a new type of multifunctional ingredient with strong potential to extend photoprotection of traditional sunscreens and daily skincare products over the first few hours after sun exposure ends.
Collapse
Affiliation(s)
- R K Chaudhuri
- Sytheon Ltd., 315 Wootton Street, Boonton, NJ, 07005, USA
| | - T Meyer
- Sytheon Ltd., 315 Wootton Street, Boonton, NJ, 07005, USA
| | - S Premi
- Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL, 33612, USA
| | - D Brash
- Department of Therapeutic Radiology, School of Medicine, Yale University, New Haven, CT, 06520, USA
| |
Collapse
|
43
|
Abou-Alfa GK, Qin S, Ryoo BY, Lu SN, Yen CJ, Feng YH, Lim HY, Izzo F, Colombo M, Sarker D, Bolondi L, Vaccaro G, Harris WP, Chen Z, Hubner RA, Meyer T, Sun W, Harding JJ, Hollywood EM, Ma J, Wan PJ, Ly M, Bomalaski J, Johnston A, Lin CC, Chao Y, Chen LT. Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma. Ann Oncol 2019; 29:1402-1408. [PMID: 29659672 DOI: 10.1093/annonc/mdy101] [Citation(s) in RCA: 134] [Impact Index Per Article: 26.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Background Arginine depletion is a putative target in hepatocellular carcinoma (HCC). HCC often lacks argininosuccinate synthetase, a citrulline to arginine-repleting enzyme. ADI-PEG 20 is a cloned arginine degrading enzyme-arginine deiminase-conjugated with polyethylene glycol. The goal of this study was to evaluate this agent as a potential novel therapeutic for HCC after first line systemic therapy. Methods and patients Patients with histologically proven advanced HCC and Child-Pugh up to B7 with prior systemic therapy, were randomized 2 : 1 to ADI-PEG 20 18 mg/m2 versus placebo intramuscular injection weekly. The primary end point was overall survival (OS), with 93% power to detect a 4-5.6 months increase in median OS (one-sided α = 0.025). Secondary end points included progression-free survival, safety, and arginine correlatives. Results A total of 635 patients were enrolled: median age 61, 82% male, 60% Asian, 52% hepatitis B, 26% hepatitis C, 76% stage IV, 91% Child-Pugh A, 70% progressed on sorafenib and 16% were intolerant. Median OS was 7.8 months for ADI-PEG 20 versus 7.4 for placebo (P = 0.88, HR = 1.02) and median progression-free survival 2.6 months versus 2.6 (P = 0.07, HR = 1.17). Grade 3 fatigue and decreased appetite occurred in <5% of patients. Two patients on ADI-PEG 20 had ≥grade 3 anaphylactic reaction. Death rate within 30 days of end of treatment was 15.2% on ADI-PEG 20 versus 10.4% on placebo, none related to therapy. Post hoc analyses of arginine assessment at 4, 8, 12 and 16 weeks, demonstrated a trend of improved OS for those with more prolonged arginine depletion. Conclusion ADI-PEG 20 monotherapy did not demonstrate an OS benefit in second line setting for HCC. It was well tolerated. Strategies to enhance prolonged arginine depletion and synergize the effect of ADI-PEG 20 are underway. Clinical Trial number www.clinicaltrials.gov (NCT 01287585).
Collapse
Affiliation(s)
- G K Abou-Alfa
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Medicine, Weill Cornell Medical College, New York, USA.
| | - S Qin
- Department of Oncology, The Chinese People's Liberation Army 81 Hospital, Nanjing, China
| | - B-Y Ryoo
- Department of Oncology, Asan Medical Center, Seoul, South Korea
| | - S-N Lu
- Department of Medical Oncology, Kaohsiung Chang Gung Memorial Hospital, Taiwan; Chang Gung University College of Medicine, Taiwan
| | - C-J Yen
- Department of Oncology, National Cheng Kung University Hospital, Taiwan
| | - Y-H Feng
- Department of Oncology, Chi Mei Medical Center-Yong Kang, Taiwan
| | - H Y Lim
- Department of Medical Oncology, Samsung Medical Center, Seoul, South Korea
| | - F Izzo
- Department of Medicine, Fondazione Giovanni Pascale, Napoli
| | - M Colombo
- Department of Medicine, Fondazione IRCCS Ca, Milan, Italy
| | - D Sarker
- Department of Medicine, King's College Hospital, London, UK
| | - L Bolondi
- Department of Medicine, Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
| | - G Vaccaro
- Department of Medicine, Oregon Health Sciences University, Portland
| | - W P Harris
- Department of Medicine, University of Washington Medical Center, Seattle, USA
| | - Z Chen
- Department of Oncology, 2nd Hospital of Anhui Medical University, Hefei, China
| | - R A Hubner
- Department of Medicine, The Christie NHS Foundation Trust, Manchester, UK
| | - T Meyer
- Department of Medicine, Royal Free Hospital and UCL Cancer Institute, London, UK
| | - W Sun
- Department of Medicine, University of Pittsburgh, Pittsburgh, USA
| | - J J Harding
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Medicine, Weill Cornell Medical College, New York, USA
| | - E M Hollywood
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - J Ma
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - P J Wan
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - M Ly
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA
| | - J Bomalaski
- Department of Research and Development, Polaris Pharmaceuticals, Inc., San Diego, USA
| | - A Johnston
- Department of Research and Development, Polaris Pharmaceuticals, Inc., San Diego, USA
| | - C-C Lin
- Department of Medical Oncology, Chang Gung Medical Foundation LK, Taipei, Tainan
| | - Y Chao
- Department of Medicine, Veterans General Hospital-Taipei, Taipei, Tainan
| | - L-T Chen
- Chang Gung University College of Medicine, Taiwan; Department of Medical Oncology, National Institute of Cancer Research, National Health Research Institutes, Tainan; Department of Oncology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
| |
Collapse
|
44
|
Guilford NGH, Lee HP, Kanger K, Meyer T, Edwards EA. Solid-State Anaerobic Digestion of Mixed Organic Waste: The Synergistic Effect of Food Waste Addition on the Destruction of Paper and Cardboard. Environ Sci Technol 2019; 53:12677-12687. [PMID: 31593445 DOI: 10.1021/acs.est.9b04644] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/12/2023]
Abstract
Full-scale anaerobic digestion processes for organic solid waste are common in Europe but are generally unaffordable in Canada and the United States because of inadequate regulations to restrict cheaper forms of disposal, particularly landfill. We investigated the viability of solid-state anaerobic digestion (SS-AD) as an alternative that reduces the costs of waste pretreatment and subsequent wastewater treatment. A laboratory SS-AD digester, comprising six 10 L leach beds and an upflow anaerobic sludge blanket reactor treating the leachate, was operated continuously for 88 weeks, with a mass balance based on chemical oxygen demand (COD) of 100 ± 2% (CODout/CODin). The feed was a mixture of fibers (cardboard, boxboard, newsprint, and fine paper) with varying amounts of food waste added. The process remained stable throughout. The addition of food waste caused a synergistic effect, raising methane production from the fiber mixture from a low of 52.7 L kg-1 COD fibersadded at no food waste, to 152 L kg-1 COD fibersadded at 29% food waste, an increase of 190%. Substrate COD destruction efficiency reached 65%, and the methane yield reached 225 L kg-1 CODadded at 29% food waste on a COD basis, with a solids retention time of 42 days. This performance was similar to that of a completely stirred tank reactor digesting similar wastes, but with much lower energy input. Multiple factors likely contributed to the enhanced fiber destruction, including the action of hydrolytic enzymes derived from fresh food waste and continuous leachate recirculation between leach beds of different ages.
Collapse
Affiliation(s)
- Nigel G H Guilford
- Department of Chemical Engineering and Applied Chemistry and BioZone , University of Toronto , 200 College Street , Toronto , Ontario , Canada M5S 3E5
| | - HyunWoo Peter Lee
- Department of Chemical Engineering and Applied Chemistry and BioZone , University of Toronto , 200 College Street , Toronto , Ontario , Canada M5S 3E5
| | - Kärt Kanger
- Department of Chemical Engineering and Applied Chemistry and BioZone , University of Toronto , 200 College Street , Toronto , Ontario , Canada M5S 3E5
- Faculty of Science and Technology , University of Tartu , Tartu , Estonia
| | - Torsten Meyer
- Department of Chemical Engineering and Applied Chemistry and BioZone , University of Toronto , 200 College Street , Toronto , Ontario , Canada M5S 3E5
| | - Elizabeth A Edwards
- Department of Chemical Engineering and Applied Chemistry and BioZone , University of Toronto , 200 College Street , Toronto , Ontario , Canada M5S 3E5
| |
Collapse
|
45
|
Yau T, Meyer T, Kelley R, Mangeshkar M, Cheng AL, El-Khoueiry A, Abou-Alfa G. Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz422.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
46
|
Chan S, Miksad R, Cicin I, Chen Y, Klumpen H, Kim S, Lin Z, Youkstetter J, Sen S, Cheng AL, El-Khoueiry A, Meyer T, Kelley R, Abou-Alfa G. Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz422.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
47
|
Zhu A, Galle P, Llovet J, Finn R, Kang YK, Yen C, Assenat E, Brandi G, Motomura K, Ohno I, Daniele B, Vogel A, Yamashita T, Hsu CH, Meyer T, Widau R, Schelman W, Wang C, Hsu Y, Kudo M. Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase III studies (REACH, REACH-2). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz247.079] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
48
|
Meyer T, Kelley R, Mangeshkar M, Cheng AL, El-Khoueiry A, Abou-Alfa G. Prognostic and predictive factors from the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz247.075] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
49
|
Naumann R, Oaknin A, Meyer T, Lopez-Picazo J, Lao C, Bang YJ, Boni V, Sharfman W, Park J, Devriese L, Harano K, Chung C, Topalian S, Zaki K, Chen T, Gu J, Li B, Barrows A, Horvath A, Moore K. Efficacy and safety of nivolumab (Nivo) + ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz394.059] [Citation(s) in RCA: 43] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
50
|
Rimassa L, Kelley R, Meyer T, Ryoo BY, Merle P, Park JW, Blanc JF, Lim H, Tran A, Borgman-Hagey A, Clary D, Wang E, Cheng AL, El-Khoueiry A, Abou-Alfa G. Outcomes based on plasma biomarkers for the phase III CELESTIAL trial of cabozantinib (C) versus placebo (P) in advanced hepatocellular carcinoma (aHCC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz247.006] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|